Bayer: FDA will speed review, give extra exclusivity for 2 respiratory drugs it's developing

Two medicines Bayer HealthCare Pharmaceuticals Inc. is testing for respiratory disorders will get priority review by U.S. regulators and other benefits under a 2012 program to boost development of new antibiotics.